| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | — | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
First Tracks Biotherapeutics is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. Its products include ANB033, an anti-CD122 antagonist targeting the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, an antibody engineered to deplete pathogenic T cells; and ANB101, a BDCA2-modulating antibody targeting plasmacytoid dendritic cells. The company is based in San Diego, California.
| Market Cap | $1.46B | Trading Days | 50 |
| 52W High | 46.45 |
| 52W Low | 14.79 |
| % Off High | −9.90% |
| Ann. Volatility (1Y) | 218.07% | Ann. Volatility (3Y) | 218.07% |
| Sharpe (1Y) | 2.71 | Sharpe (3Y) | 2.71 |
| Max Drawdown (1Y) | −32.45% | Max Drawdown (3Y) | −32.45% |
| YTD | 125.00% | Since inception | 125.00% |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CMPS | COMPASS Pathways plc | $1.47B | — |
| XNCR | Xencor Inc | $1.45B | — |
| XERS | Xeris Biopharma Holdings, Inc. | $1.45B | — |
| PRGO | PERRIGO Co plc | $1.44B | — |
| HROW | HARROW, INC. | $1.44B | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $1.50B | 31.1 |
| SEPN | Septerna, Inc. | $1.51B | — |
| ANAB | ANAPTYSBIO, INC | $1.52B | — |
| AVBP | ArriVent BioPharma, Inc. | $1.40B | — |
| MLTX | MoonLake Immunotherapeutics | $1.35B | — |
| INVA | Innoviva, Inc. | $1.60B | 6.6 |
| ZYME |
| Zymeworks Inc. |
| $1.61B |
| — |
